Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

被引：15
|
作者：
Mascarenhas, John [1 ]
Baer, Maria R. [2 ]
Kessler, Craig [3 ]
Hexner, Elizabeth [4 ]
Tremblay, Douglas [1 ]
Price, Leah [5 ]
Sandy, Lonette [1 ]
Weinberg, Rona [6 ]
Pahl, Heike [7 ]
Silverman, Lewis R. [1 ]
Goldberg, Judith D. [5 ]
Kosiorek, Heidi [8 ]
Dueck, Amylou C. [8 ]
Hoffman, Ronald [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, One Gustave L Levy Pl,Box 1079, New York, NY 10029 USA
[2] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[3] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] NYU, Dept Populat Hlth, New York, NY USA
[6] New York Blood Ctr, Myeloproliferat Disorders Lab, New York, NY 10021 USA
[7] Univ Med Ctr Freiburg, Dept Hematol Oncol, Sect Mol Hematol, Freiburg, Germany
[8] Mayo Clin Arizona, Div Biostat, Scottsdale, AZ USA
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 05期
关键词：
RUXOLITINIB; THERAPY;
D O I：
10.1080/10428194.2018.1532509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1343 / 1345
页数：3
相关论文
共 50 条
  • [1] Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis
    Deeg, H. J.
    Odenike, O.
    Scott, B. L.
    Estrov, Z.
    Cortes, J. E.
    Thomas, D. A.
    Zhu, H. J.
    Kantarjian, H.
    Verstovsek, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] JAK2 inhibitor treatment of anemia in myelofibrosis
    Tefferi, Ayalew
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : 995 - 997
  • [3] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2012, 120 (21)
  • [4] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
    Komrokji, Rami S.
    Seymour, John F.
    Roberts, Andrew W.
    Wadleigh, Martha
    To, L. Bik
    Scherber, Robyn
    Turba, Elyce
    Dorr, Andrew
    Zhu, Joy
    Wang, Lixia
    Granston, Tanya
    Campbell, Mary S.
    Mesa, Ruben A.
    BLOOD, 2015, 125 (17) : 2649 - 2655
  • [5] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [6] Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman, Guido
    Mascarenhas, John
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (01) : 23 - 28
  • [7] Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Tefferi, Ayalew
    Korriblau, Steven
    Thomas, Deborah
    Cortes, Jorge
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 1037A - 1037A
  • [8] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [9] ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
    Oh, Stephen T.
    Talpaz, Moshe
    Gerds, Aaron T.
    Gupta, Vikas
    Verstovsek, Srdan
    Mesa, Ruben
    Miller, Carole B.
    Rivera, Candido E.
    Fleischman, Angela G.
    Goel, Swati
    Heaney, Mark L.
    O'Connell, Casey
    Arcasoy, Murat O.
    Zhang, Yafeng
    Kawashima, Jun
    Ganz, Tomas
    Kowalski, Mark
    Brachmann, Carrie Baker
    BLOOD ADVANCES, 2020, 4 (18) : 4282 - 4291
  • [10] SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT
    Scherber, R.
    Dueck, A.
    Geyer, H.
    Kosiorek, H.
    Kiladjian, J. J.
    Slot, S.
    Zweegman, S.
    Boekhorst, P.
    Schouten, H.
    Sackmann, F.
    Fuentes, A.
    Hernandez-Maraver, D.
    Pahl, H.
    Stegelmann, F.
    Doehner, K.
    Bonatz, K.
    Reiter, A.
    Boyer, F.
    Etienne, G.
    Ianotto, J. C.
    Ranta, D.
    Roy, L.
    Cahn, J. Y.
    Harrison, C.
    Radia, D.
    Muxi, P.
    Maldonado, N.
    Besses, C.
    Cervantes, F.
    Johansson, P.
    Barosi, G.
    Vannucchi, A.
    Passamonti, F.
    Andreasson, B.
    Samuelsson, J.
    Birgegard, G.
    Sun, X.
    Xu, J.
    Zhang, P.
    Xu, Z.
    Barbui, T.
    Barbui, T.
    Senyak, Z.
    Grieshammer, M.
    Rambaldi, A.
    Ferrari, M.
    Lehmann, T.
    Mesa, R.
    HAEMATOLOGICA, 2016, 101 : 557 - 558
12345